Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Glucose metabolism controls disease-specific signatures of macrophage effector functions
Ryu Watanabe, … , Jörg J. Goronzy, Cornelia M. Weyand
Ryu Watanabe, … , Jörg J. Goronzy, Cornelia M. Weyand
Published October 18, 2018
Citation Information: JCI Insight. 2018;3(20):e123047. https://doi.org/10.1172/jci.insight.123047.
View: Text | PDF
Clinical Research and Public Health Metabolism Vascular biology

Glucose metabolism controls disease-specific signatures of macrophage effector functions

  • Text
  • PDF
Abstract

BACKGROUND. In inflammatory blood vessel diseases, macrophages represent a key component of the vascular infiltrates and are responsible for tissue injury and wall remodeling. METHODS. To examine whether inflammatory macrophages in the vessel wall display a single distinctive effector program, we compared functional profiles in patients with either coronary artery disease (CAD) or giant cell arteritis (GCA). RESULTS. Unexpectedly, monocyte-derived macrophages from the 2 patient cohorts displayed disease-specific signatures and differed fundamentally in metabolic fitness. Macrophages from CAD patients were high producers for T cell chemoattractants (CXCL9, CXCL10), the cytokines IL-1β and IL-6, and the immunoinhibitory ligand PD-L1. In contrast, macrophages from GCA patients upregulated production of T cell chemoattractants (CXCL9, CXCL10) but not IL-1β and IL-6, and were distinctly low for PD-L1 expression. Notably, disease-specific effector profiles were already identifiable in circulating monocytes. The chemokinehicytokinehiPD-L1hi signature in CAD macrophages was sustained by excess uptake and breakdown of glucose, placing metabolic control upstream of inflammatory function. CONCLUSIONS. We conclude that monocytes and macrophages contribute to vascular inflammation in a disease-specific and discernible pattern, have choices to commit to different functional trajectories, are dependent on glucose availability in their immediate microenvironment, and possess memory in their lineage commitment. FUNDING. Supported by the NIH (R01 AR042527, R01 HL117913, R01 AI108906, P01 HL129941, R01 AI108891, R01 AG045779 U19 AI057266, R01 AI129191), I01 BX001669, and the Cahill Discovery Fund.

Authors

Ryu Watanabe, Marc Hilhorst, Hui Zhang, Markus Zeisbrich, Gerald J. Berry, Barbara B. Wallis, David G. Harrison, John C. Giacomini, Jörg J. Goronzy, Cornelia M. Weyand

×

Figure 5

Monocyte-derived macrophages from CAD patients are highly efficient in glucose import and glycolytic activity.

Options: View larger image (or click on image) Download as PowerPoint
Monocyte-derived macrophages from CAD patients are highly efficient in g...
Macrophages from HC, GCA patients, and CAD patients were differentiated from blood monocytes as in Figure 1 and stimulated with LPS/IFN-γ for 24 hours. (A) Gene transcripts for the main glucose transporter (GLUT1), the glycolytic enzymes, and transcription factors regulating glycolysis were quantified by RT-PCR (n = 6 each). Three out of 6 CAD patients were diabetic. Gene expression is displayed as heatmaps with data presented as log2 values. (B and C) Surface GLUT1 expression analyzed by flow cytometry. (B) Representative histograms. (C) Summary from 6 independent experiments. (D and E) Mitochondrial ROS production was measured by flow cytometry using mitoSOX. (D) Representative histograms. (E) Summary from 6 experiments. Data are mean ± SEM and were analyzed by 1-way ANOVA (A) or 2-way ANOVA (C and E) with Tukey’s multiple comparison test. ***P < 0.001. CAD, coronary artery disease; CCL, C-C motif chemokine ligand; CXCL, C-X-C motif chemokine ligand; DM, diabetes mellitus; FMO, fluorescence minus one; HC, healthy control; HK2, hexokinase 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GCA, giant cell arteritis; GLUT1, glucose transporter 1; HIF-1α, hypoxia-inducible factor 1α; IFN-γ, interferon γ; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; MFI, mean fluorescence intensity; ns, not significant; PFK1, phosphofructokinase 1; PKM2, pyruvate kinase M2; Rel. Exp., relative expression; ROS, reactive oxygen species; RT-PCR, reverse transcription polymerase chain reaction.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts